Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-Fresenius S and rituximab for GVHD immunomodulation in allogeneic matched transplants for non-malignant diseases
2011-004730-34Phase 2Terminated
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of antithymocyte globulin rabbit and rituximab in graft-versus-host disease (GVHD) (4 arms), sponsored by Ospedale Pediatrico Bambino Gesù. Started Mar 2012; status: terminated.
02
Drugs
antithymocyte globulin rabbitrituximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2011-004730-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004730-34.